SCHEMBL168737

SCHEMBL168737

O=C(OCc1ccccc1)c1cc(Cl)c(C(=O)N2CCOCC2)cc1OCc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.53
ALDH1A1 P00352 3/20 0.52
KMT2A Q03164 4/20 0.51
NPSR1 Q6W5P4 3/20 0.51
MEN1 O00255 2/20 0.51
CNR1 P21554 1/20 0.49
KDM4E B2RXH2 3/20 0.48
LMNA P02545 3/20 0.48
MAPT P10636 2/20 0.48
HTT P42858 2/20 0.48
HPGD P15428 2/20 0.48
TSHR P16473 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
APP P05067 1/20 0.47
NMT2 O60551 1/20 0.47
NMT1 P30419 1/20 0.47
PKM P14618 1/20 0.45
GAA P10253 1/20 0.45
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL168000 0.90 HTT (0.56) HSD17B10ALDH1A1KMT2ANPSR1MEN1
SCHEMBL168475 0.88 HSD17B10 (0.53) HSD17B10ALDH1A1KMT2ANPSR1MEN1
SCHEMBL167413 0.88 HPGD (0.52) ALDH1A1KMT2ANPSR1MEN1LMNA
SCHEMBL166546 0.85 HSD17B10 (0.50) HSD17B10ALDH1A1KMT2ANPSR1MEN1
SCHEMBL169355 0.82 DPP4 (0.42) ALDH1A1KMT2ANPSR1MEN1LMNA
SCHEMBL257054 0.81 LRRK2 (0.58) HSD17B10ALDH1A1KMT2AMEN1KDM4E
SCHEMBL165087 0.81 ALDH1A1 (0.57) ALDH1A1KMT2AMEN1KDM4EHTT
SCHEMBL257195 0.79 LRRK2 (0.61)
SCHEMBL257053 0.79 LRRK2 (0.68)
SCHEMBL4473338 0.78 HSD17B10 (0.61) HSD17B10ALDH1A1KMT2ANPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 HSD17B10 2900/4885ALDH1A1 3544/4885KMT2A 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.